Eurostib 200 mg Tablet
PDF Leaflet Revision Date: 11 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma.
Dosage (summary)
400 mg daily (2 x 200 mg tablets) taken twice daily.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential for teratogenic effects.
Key Drug Interactions
- Warfarin
- Docetaxel
- Neomycin
Contraindications
- Hypersensitivity to sorafenib
- Pregnancy
- Lactation
Common side effects
- Diarrhoea
- Fatigue
- Alopecia
- Rash
- Hand foot skin reaction
Counselling Points
- Avoid pregnancy during treatment
- Monitor blood pressure regularly
- Report any signs of bleeding
Serious warnings
- Hypertension
- Cardiac ischaemia
- Gastrointestinal perforation
- QT prolongation
Important Disclaimer
The Eurostib 200 mg Tablet professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
